In our ongoing attempt to identify pharmacologic interventions that improve fracture healing, the sclerostin inhibitor romosozumab is a logical candidate, as it has been shown
Tag: romosozumab
We have all come to realize that promising results from lab studies or preclinical trials in animal models do not always translate into meaningful clinical